Ryan C Lynch

18PUBLICATIONS
100CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 14, 2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

|Jul 17, 2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

|Dec 29, 2025
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Jeremy S Abramson, David J Straus, Nancy L Bartlett

|Oct 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Edward R Scheffer Cliff, Guido D Pelaez, Fei Wan

|Oct 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.

Ryan C Lynch, Ryan D Cassaday, Stephen D Smith

|Aug 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Mark Roschewski, David M Kurtz, Jason R Westin

Pageof 3

Frequent Collaborators

9 joint publications

Mazyar Shadman

8 joint publications

Stephen D Smith

7 joint publications

Chaitra Ujjani

5 joint publications

Edus H Warren